The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISTH 2024 | An overview of the remaining challenges for patients with hemophilia
In this video, Matteo Luciani, MD, Bambino Gesù Children’s Hospital, Rome, Italy, discusses the remaining challenges for patients with hemophilia. In infancy, subcutaneous factor VIII therapies are needed as venous access for intravenous therapy is difficult. The frequency of infusions patients need, which can reach three times a week in hemophilia A, is another challenge affecting all ages, particularly adolescents. It is hoped that novel agents will reduce administration frequency. Finally, whilst gene therapies appear to be quite promising for hemophilia B, they have several limitations which may prevent their use in clinical practice for hemophilia A. This interview took place at the 32nd Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Bangkok, Thailand, and virtually.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
